Stock listing
NASDAQ:BCDA BioCardia, Inc. Stock
Home listing (NASDAQ) of BioCardia, Inc.
Follow BioCardia, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BCDA
$0.785 USD +0.013 (+1.7%)
Close on Nov 20, 2026
- Day range
- $0.720 – $0.799 USDNov 20, 2026
- Volume
- 350,429 sharesNov 20, 2026
- Market cap
- $11.88M USDAt the close on Nov 20, 2026 · price × 15.14M shares outstanding
- 52-week range
- $0.661 – $1.800 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $217,942 USDMedian day 129,616 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BCDA · Home | $0.785 USD | +0.013 (+1.7%) | 350,429 | $0.749 | $0.799 | $0.720 | $0.772 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BCDA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.785 | +0.013 | +1.7% | $0.749 | $0.799 | $0.720 | 350,429 | |
| $0.772 | -0.016 | -2.1% | $0.849 | $0.849 | $0.760 | 22,925 | |
| $0.788 | -0.002 | -0.2% | $0.763 | $0.800 | $0.749 | 41,869 | |
| $0.790 | -0.041 | -4.9% | $0.837 | $0.850 | $0.751 | 60,744 | |
| $0.831 | +0.005 | +0.6% | $0.970 | $0.970 | $0.815 | 78,300 | |
| $0.826 | -0.096 | -10.4% | $0.950 | $0.950 | $0.661 | 287,877 | |
| $0.922 | -0.009 | -0.9% | $0.927 | $0.980 | $0.910 | 58,184 | |
| $0.930 | +0.028 | +3.1% | $0.900 | $0.965 | $0.900 | 36,847 | |
| $0.903 | +0.053 | +6.2% | $0.890 | $0.960 | $0.850 | 117,698 | |
| $0.850 | -0.040 | -4.5% | $0.930 | $0.930 | $0.850 | 167,664 | |
| $0.890 | -0.023 | -2.5% | $0.892 | $0.910 | $0.840 | 136,810 | |
| $0.913 | -0.008 | -0.9% | $0.970 | $0.970 | $0.884 | 110,558 | |
| $0.922 | +0.020 | +2.2% | $0.936 | $0.978 | $0.903 | 70,085 | |
| $0.902 | +0.041 | +4.8% | $0.868 | $1.000 | $0.860 | 81,691 | |
| $0.861 | -0.065 | -7.0% | $0.920 | $0.920 | $0.861 | 78,713 | |
| $0.926 | -0.021 | -2.3% | $0.963 | $1.000 | $0.926 | 47,056 | |
| $0.947 | +0.026 | +2.8% | $0.935 | $0.947 | $0.922 | 19,925 | |
| $0.922 | +0.020 | +2.2% | $0.900 | $0.928 | $0.870 | 37,114 | |
| $0.902 | -0.020 | -2.1% | $0.921 | $0.929 | $0.870 | 129,616 | |
| $0.921 | -0.008 | -0.8% | $0.948 | $0.950 | $0.912 | 40,315 | |
| $0.929 | -0.054 | -5.5% | $0.976 | $0.986 | $0.920 | 50,139 | |
| $0.982 | -0.058 | -5.5% | $1.050 | $1.050 | $0.970 | 133,411 | |
| $1.040 | +0.143 | +15.9% | $0.900 | $1.070 | $0.900 | 217,707 | |
| $0.898 | -0.023 | -2.4% | $0.900 | $1.020 | $0.881 | 439,732 | |
| $0.920 | -0.020 | -2.1% | $0.950 | $0.960 | $0.910 | 104,800 | |
| $0.940 | +0.010 | +1.1% | $0.940 | $0.970 | $0.870 | 236,300 | |
| $0.930 | -0.060 | -6.1% | $1.000 | $1.000 | $0.910 | 146,400 | |
| $0.990 | -0.030 | -2.9% | $1.020 | $1.030 | $0.980 | 68,000 | |
| $1.020 | -0.020 | -1.9% | $1.040 | $1.040 | $1.000 | 80,300 | |
| $1.040 | -0.020 | -1.9% | $1.060 | $1.080 | $1.020 | 101,900 | |
| $1.060 | -0.030 | -2.8% | $1.070 | $1.090 | $1.050 | 162,400 | |
| $1.090 | +0.030 | +2.8% | $1.070 | $1.090 | $1.030 | 167,800 | |
| $1.060 | -0.030 | -2.8% | $1.100 | $1.110 | $1.050 | 113,400 | |
| $1.090 | +0.050 | +4.8% | $1.060 | $1.090 | $1.040 | 148,400 | |
| $1.040 | +0.020 | +2.0% | $1.040 | $1.050 | $1.030 | 52,500 | |
| $1.020 | +0.010 | +1.0% | $1.000 | $1.050 | $0.990 | 205,900 | |
| $1.010 | -0.020 | -1.9% | $1.040 | $1.040 | $1.010 | 90,700 | |
| $1.030 | -0.010 | -1.0% | $1.050 | $1.070 | $1.000 | 117,300 | |
| $1.040 | -0.010 | -1.0% | $1.050 | $1.090 | $1.040 | 159,200 | |
| $1.050 | -0.020 | -1.9% | $1.080 | $1.080 | $1.050 | 51,200 | |
| $1.070 | +0.020 | +1.9% | $1.030 | $1.090 | $1.030 | 122,500 | |
| $1.050 | 0.000 | 0.0% | $1.030 | $1.080 | $1.030 | 141,000 | |
| $1.050 | -0.030 | -2.8% | $1.030 | $1.100 | $0.980 | 497,400 | |
| $1.080 | -0.090 | -7.7% | $1.180 | $1.190 | $1.060 | 2,080,400 | |
| $1.170 | +0.060 | +5.4% | $1.120 | $1.210 | $1.100 | 169,900 | |
| $1.110 | -0.140 | -11.2% | $1.250 | $1.260 | $1.100 | 416,300 | |
| $1.250 | +0.020 | +1.6% | $1.240 | $1.400 | $1.130 | 1,529,300 | |
| $1.230 | +0.040 | +3.4% | $1.190 | $1.290 | $1.190 | 518,700 | |
| $1.190 | +0.110 | +10.2% | $1.100 | $1.230 | $1.100 | 595,100 | |
| $1.080 | -0.020 | -1.8% | $1.120 | $1.140 | $1.080 | 137,000 | |
| $1.100 | 0.000 | 0.0% | $1.090 | $1.110 | $1.070 | 80,000 | |
| $1.100 | -0.010 | -0.9% | $1.110 | $1.140 | $1.090 | 91,000 | |
| $1.110 | +0.030 | +2.8% | $1.090 | $1.140 | $1.080 | 130,300 | |
| $1.080 | -0.010 | -0.9% | $1.070 | $1.090 | $1.060 | 57,300 | |
| $1.090 | -0.020 | -1.8% | $1.120 | $1.130 | $1.070 | 168,500 | |
| $1.110 | +0.010 | +0.9% | $1.110 | $1.130 | $1.100 | 51,000 | |
| $1.100 | -0.040 | -3.5% | $1.130 | $1.130 | $1.080 | 68,500 | |
| $1.140 | -0.010 | -0.9% | $1.140 | $1.170 | $1.100 | 141,700 | |
| $1.150 | -0.020 | -1.7% | $1.170 | $1.200 | $1.110 | 159,000 | |
| $1.170 | -0.020 | -1.7% | $1.180 | $1.230 | $1.170 | 211,600 | |
| $1.190 | +0.060 | +5.3% | $1.130 | $1.210 | $1.100 | 244,500 | |
| $1.130 | +0.070 | +6.6% | $1.060 | $1.140 | $1.020 | 354,000 | |
| $1.060 | +0.050 | +5.0% | $1.000 | $1.060 | $0.980 | 272,400 | |
| $1.010 | +0.040 | +4.1% | $0.970 | $1.020 | $0.960 | 82,500 | |
| $0.970 | -0.020 | -2.0% | $1.000 | $1.000 | $0.950 | 156,200 |
Splits
6 splits since 2001 · NASDAQ:BCDA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation | |
| 1-for-9 | Consolidation | |
| 1-for-12 | Consolidation | |
| 1-for-10 | Consolidation | |
| 6-for-1 | Split | |
| 1-for-3 | Consolidation |
- Ticker
- NASDAQ:BCDA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
Latest earnings call · Nov 12, 2026
BioCardia (NASDAQ:BCDA) Q3 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 23 slides
Latest news
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
Nov 12, 2026
Closed $0.831 (+0.6%) on Nov 13, 2026
BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026
Nov 9, 2026
Closed $0.93 (+3.1%) on Nov 10, 2026
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
Nov 6, 2026
Closed $0.85 (-4.5%) on Nov 6, 2026
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
Oct 19, 2026
Closed $0.898 (-2.4%) on Oct 19, 2026
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
Oct 7, 2026
Closed $1.09 (+2.8%) on Oct 7, 2026
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
Oct 1, 2026
Closed $1.02 (+1.0%) on Oct 1, 2026
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
Sep 23, 2026
Closed $1.05 (0.0%) on Sep 23, 2026
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
Sep 10, 2026
Closed $1.10 (0.0%) on Sep 10, 2026
BioCardia: Aug 24 - BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-on De Novo Pre-submission For Approval
Aug 24, 2026
Closed $1.06 (+5.0%) on Aug 24, 2026
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
Aug 12, 2026
Closed $0.93 (+5.7%) on Aug 13, 2026
BioCardia, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 35 in the last 12 months · 188 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 20 calls with a replay · 20 with a transcript · latest Nov 12, 2026
- Decks
- 18 decks · latest November 2026
Where BioCardia, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BCDA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BCDA | BOATS | United States | USD |
| Frankfurt:6JU0 | Frankfurt | Germany | EUR |
| gettex:6JU0 | gettex | Germany | EUR |
| Lang & Schwarz:A40D1S | Lang & Schwarz | Germany | EUR |
Valuation
Price/book 14.2× against a median of 2.0×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $10.22M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 14.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.7×
- Beta vs S&P 500
- 0.42
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioCardia, Inc. · NASDAQ:BCDA | US$11.88M | US$10.22M | n/a | n/a | n/a | 14.2× | n/a | 0.7× | 0.42 |
| MIRA Pharmaceuticals, Inc. · NASDAQ:MIRA | US$12.23M | US$5.26M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 1.48 |
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| Xintela AB · OMXSTO:XINT | US$11.88M | US$11.81M | n/a | 39.8× | n/a | n/a | n/a | n/a | n/a |
| Pluri Inc. · NASDAQ:PLUR | US$11.85M | US$38.65M | n/a | 26.5× | n/a | n/a | n/a | n/a | 0.53 |
| Synlogic Inc · OTC:SYBX | US$11.76M | US$201,442 | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 0.50 |
| Imugene Ltd · ASX:IMU | US$11.74M | US$14.16M | n/a | n/a | n/a | 2.0× | n/a | 0.7× | n/a |
| Radiopharm Theranostics Limited · ASX:RAD | US$11.59M | US$8.85M | n/a | 4.8× | n/a | 0.7× | n/a | 0.0× | n/a |
| Aelis Farma SA · EURONEXT:AELIS | US$11.55M | US$9.09M | n/a | 4.0× | n/a | 4.5× | −308.7% | 1.9× | n/a |
| Simris Group AB Class B · OMXSTO:SIMRIS_B | US$11.54M | US$19.53M | n/a | 144× | n/a | 154× | n/a | 117× | n/a |
| Dyadic International, Inc. · NASDAQ:DYAI | US$11.51M | US$12.03M | n/a | 3.9× | n/a | n/a | −226.9% | n/a | 1.12 |
| Median of the others | US$11.75M | US$11.52M | 15.7× | 2.0× | −267.8% | 0.0× | 0.83 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.63 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Peter Altman | President and Chief Executive Officer |
| David McClung | CFO |
| Bill Facteau | President |
| Miranda Peto | Investor Relations |
| Debby Holmes-Higgin | VP of Clinical |
| Edward Gillis | Sr. VP of Devices |
Board
| Director | Role |
|---|---|
| Andrew Scott Blank | Chairman of our board of directors |
| Jay M. Moyes | Board Member |
| Marvin Slosman | Board Member |
| Peter Altman | President and Chief Executive Officer |
| Simon H. Stertzer | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| BioCardia (NASDAQ:BCDA) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q1 2026 Earnings Call | Fri, May 15, 2026 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q4 2025 Earnings Call | Tue, Mar 24, 2026 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q2 2025 Earnings Call | Mon, Aug 11, 2025 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q1 2025 Earnings Call | Wed, May 14, 2025 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q4 2024 Earnings Call | Mon, Mar 31, 2025 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q3 2024 Earnings Call | Wed, Nov 13, 2024 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q2 2024 Earnings Call | Tue, Aug 13, 2024 · 4:30 PM ET | Replay |
All 20 calls
| Call | When | Status |
|---|---|---|
| BioCardia (NASDAQ:BCDA) Q1 2024 Earnings Call | Tue, May 14, 2024 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q4 2023 Earnings Call | Wed, Mar 27, 2024 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q3 2023 Earnings Call | Wed, Nov 08, 2023 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q2 2023 Earnings Call | Wed, Aug 09, 2023 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q1 2023 Earnings Call | Wed, May 10, 2023 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q4 2022 Earnings Call | Wed, Mar 29, 2023 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q3 2022 Earnings Call | Wed, Nov 09, 2022 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q2 2022 Earnings Call | Wed, Aug 10, 2022 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q1 2022 Earnings Call | Wed, May 11, 2022 · 4:30 PM ET | Replay |
| BioCardia (NASDAQ:BCDA) Q4 2021 Earnings Call | Tue, Mar 29, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +0.6% |
| Q2 2026 | Aug 12, 2026 · After close | +5.7% |
| Q1 2026 | May 15, 2026 | −17.4% |
| Q4 2025 | Mar 24, 2026 · After close | −0.4% |
| Q3 2025 | Nov 12, 2025 · After close | −3.1% |
| Q2 2025 | Aug 11, 2025 · Before open | −6.2% |
| Q1 2025 | May 14, 2025 · After close | −16.3% |
| Q4 2024 | Mar 25, 2025 · Before open | +1.1% |
| Q3 2024 | Nov 13, 2024 · After close | −14.3% |
| Q2 2024 | Aug 13, 2024 · After close | −1.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | +1.0% |
| Q4 2023 | Mar 27, 2024 · After close | −2.9% |
| Q3 2023 | Nov 8, 2023 · After close | −5.8% |
| Q2 2023 | Aug 9, 2023 · After close | −0.4% |
| Q1 2023 | May 10, 2023 · After close | +0.5% |
| Q4 2022 | Mar 29, 2023 · Before open | −4.6% |
| Q3 2022 | Nov 9, 2022 · After close | −3.0% |
| Q2 2022 | Aug 10, 2022 · After close | +5.3% |
| Q1 2022 | May 11, 2022 · After close | +11.9% |
| Q4 2021 | Mar 29, 2022 · After close | −2.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 23 slides | November 2026 |
| Investor Presentation (August 2026) | Investor deck | 24 slides | August 2026 |
| Q1 2026 Earnings Presentation | Earnings | 19 slides | May 15, 2026 |
| Technical Presentation (April 2026) | Technical | 36 slides | Apr 28, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 22 slides | Mar 24, 2026 |
| Investor Presentation (September 2025) | Investor deck | 35 slides | September 2025 |
| Q1 2025 Earnings Presentation | Earnings | 38 slides | May 14, 2025 |
| Investor Presentation (March 2025) | Investor deck | 31 slides | March 2025 |
| Investor Presentation (November 2024) | Investor deck | 24 slides | November 2024 |
| Technical Presentation (April 2024) | Technical | 13 slides | Apr 30, 2024 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2024) | Investor deck | 27 slides | March 2024 |
| Next Generation Cardiovascular Drug Development Summit (April 2023) | Conference | 24 slides | Apr 28, 2023 |
| Investor Presentation (March 2023) | Investor deck | 21 slides | Mar 29, 2023 |
| Investor Presentation (June 2021) | Investor deck | 27 slides | June 2021 |
| Forum for Innovative Regenerative Medicine, Regenerative Medicine Cross Roads (January 2019) | Conference | 27 slides | Jan 28, 2019 |
| Technical Presentation (November 2018) | Technical | 12 slides | Nov 14, 2018 |
| ARM Partnering Presentation (October 2015) | Conference | 17 slides | Oct 7, 2015 |
| IPO Roadshow (October 2015) | IPO roadshow | 17 slides | Oct 6, 2015 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and short-term warrants Announced: US$6M · US$1.25 a share · Warrants at US$1.25 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes, including advancing biotherapeutic candidates and the delivery partnering business | Sep 18, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 58.0K | 477.0K | 1.35M | 1.01M | 145.0K | 710.0K | 625.0K | 479.0K | 576.0K |
| Cost of revenue | 505.0K | 4.39M | 7.73M | 11.9M | 0 | 4.00K | 358.0K | 517.0K | 690.0K | 746.0K |
| Gross profit | -505.0K | -4.33M | -7.25M | -10.5M | 375.0K | 141.0K | 352.0K | 108.0K | -211.0K | -170.0K |
| Research and development | 4.96M | 4.39M | 7.73M | 8.83M | 8.56M | 9.81M | 8.56M | 8.45M | 5.80M | 3.33M |
| Selling, general and administrative | 3.32M | 3.67M | 4.39M | 4.42M | 5.09M | 5.86M | 6.00M | 5.76M | 6.39M | 4.11M |
| Operating income | -8.28M | -8.00M | -11.6M | -11.9M | -12.6M | -15.5M | -14.2M | -14.1M | -12.4M | -7.61M |
| Depreciation and amortization | 24.0K | 67.0K | 84.0K | 82.0K | 60.0K | 68.0K | 111.0K | 88.0K | 78.0K | 39.0K |
| EBITDA | -8.25M | -7.93M | -11.6M | -11.8M | -12.6M | -15.5M | -14.1M | -14.0M | -12.3M | -7.57M |
| Interest expense | 6.00K | 0 | 3.00K | 112.0K | 118.0K | 0 | 1.74M | |||
| Income before tax | -8.23M | -7.95M | -11.6M | -11.9M | -12.6M | -15.0M | -14.7M | -14.0M | -12.3M | -10.3M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -8.23M | -7.95M | -11.6M | -11.9M | -12.6M | -15.0M | -14.7M | -14.0M | -12.3M | -10.3M |
| Earnings per share, basic | -1.23 | -2.90 | -8.19 | -0.67 | -0.75 | -1.48 | -2.61 | -3.28 | -2.90 | -1.23 |
| Earnings per share, diluted | -0.75 | -1.48 | -2.61 | -3.28 | -2.90 | -1.23 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.50M | 2.37M | 1.10M | 7.36M | 12.9M | 21.4M | 5.58M | 5.36M | 12.7M | 21.4M |
| Receivables | 20.0K | 0 | 63.0K | 201.0K | 147.0K | 232.0K | 147.0K | 274.0K | 95.0K | 74.0K |
| Inventory | -201.0K | 1 | -850.0K | 4.00K | 141.0K | 191.0K | 135.0K | |||
| Current assets | 2.73M | 2.62M | 1.46M | 7.86M | 13.5M | 22.7M | 6.38M | 6.22M | 13.3M | 21.9M |
| Property, plant and equipment | 16.0K | 33.0K | 94.0K | 170.0K | 182.0K | 145.0K | 181.0K | 145.0K | 169.0K | 111.0K |
| Total assets | 3.41M | 3.72M | 2.99M | 9.79M | 15.7M | 23.4M | 7.68M | 6.42M | 13.5M | 22.1M |
| Accounts payable | 641.0K | 385.0K | 890.0K | 683.0K | 507.0K | 746.0K | 914.0K | 743.0K | 902.0K | 525.0K |
| Current liabilities | 2.43M | 2.32M | 3.61M | 3.58M | 3.71M | 4.25M | 4.00M | 2.55M | 2.33M | 1.44M |
| Total debt | 528.0K | 951.0K | 1.31M | 1.63M | 1.87M | 614.0K | 1.14M | |||
| Total liabilities | 2.52M | 2.89M | 4.59M | 4.90M | 5.34M | 4.25M | 5.31M | 2.63M | 2.41M | 1.50M |
| Shareholders' equity | 895.0K | 837.0K | -1.60M | 4.89M | 10.4M | 19.2M | 2.37M | 3.79M | 11.1M | 20.6M |
| Shares outstanding | 10.8M | 4.60M | 1.58M | 20.1M | 16.9M | 16.3M | 6.83M | 4.85M | 38.2M | 38.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7.44M | -7.89M | -9.97M | -10.6M | -10.4M | -12.4M | -9.45M | -11.1M | -8.67M | -5.52M |
| Capital spending | -7.00K | -6.00K | -12.0K | -70.0K | -116.0K | -32.0K | -146.0K | -66.0K | -136.0K | -136.0K |
| Free cash flow | -7.44M | -7.89M | -9.99M | -10.6M | -10.5M | -12.4M | -9.59M | -11.1M | -8.81M | -5.52M |
| Cash from investing | -7.00K | -6.00K | -12.0K | -70.0K | -116.0K | -32.0K | -146.0K | -66.0K | -136.0K | 18.9M |
| Cash from financing | 7.57M | 9.16M | 3.73M | 5.12M | 1.95M | 28.2M | 9.82M | 3.80M | 144.0K | 4.40M |
| Dividends paid | -346.0K | |||||||||
| Share buybacks | -160.0K | 9.19M | 3.80M | 144.0K | 4.40M | |||||
| Change in cash | 125.0K | 1.27M | -6.26M | -5.51M | -8.54M | 15.8M | 227.0K | -7.33M | -8.66M | 17.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
| 8-K · Current report | Oct 7, 2026 | Current report | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 23, 2026 | Current report | SEC |
| 8-K · Current report | Sep 21, 2026 | Current report | SEC |
| 8-K · Current report | Sep 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 24, 2026 | Current report | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Current report | SEC |
| 8-K · Current report | Jun 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| 8-K · Current report | Jun 5, 2026 | Current report | SEC |
| 8-K · Current report | May 28, 2026 | Current report | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| 8-K · Current report | Apr 15, 2026 | Current report | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 24, 2026 | Results | SEC |
| S-8 · Registration statement for employee plans | Mar 24, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 24, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2026 | Current report | SEC |
| 8-K · Current report | Mar 3, 2026 | Current report | SEC |
| 8-K · Current report | Feb 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 18, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 16, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 3, 2025 | Management or board change | SEC |
| 8-K · Current report | Nov 24, 2025 | Current report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Nov 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| 10-Q/A · Quarterly report, amended | Oct 29, 2025 | Quarterly report | SEC |
| 424B5 · Prospectus | Oct 24, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 7, 2025 | Current report | SEC |
| 8-K · Current report | Oct 2, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 24, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 22, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 19, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 19, 2025 | Current report | SEC |
| 424B4 · Prospectus | Sep 19, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 19, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Sep 17, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 17, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 16, 2025 | Other filings | SEC |
| S-1 · Registration statement | Sep 16, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 8-K · Current report | Aug 4, 2025 | Current report | SEC |
| 8-K · Current report | Jul 24, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 18, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 18, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 16, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Jul 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 15, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 14, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 9, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jul 8, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2025 | Financing | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | May 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 21, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | May 5, 2025 | Other filings | SEC |
| 8-K · Current report | May 1, 2025 | Current report | SEC |
| S-3 · Registration statement | Apr 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 23, 2025 | Financing | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 11, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Apr 4, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 4, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2025 | Current report | SEC |
| 8-K · Current report | Mar 31, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 26, 2025 | Results | SEC |
| 10-K · Annual report | Mar 26, 2025 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Mar 20, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Mar 17, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 27, 2025 | Current report | SEC |
| 8-K · Current report | Feb 13, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 27, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 17, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 17, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 4, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 2, 2024 | Offer document | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 18, 2024 | Current report | SEC |
| 8-K · Current report | Sep 9, 2024 | Current report | SEC |
This page holds 200 of 1,002 filings. Open Filings
Cap table
Built by 6ix from BioCardia, Inc.’s releases · as of Nov 11, 2026
- Common shares
- 15,138,782
- Fully diluted
- 15,138,782
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 15,138,782 | Nov 11, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 15,138,782 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jay M. Moyes Other companies: SiNtx Technologies, Inc. (Audit Committee Chair · Since at least Apr 3, 2025); Puma Biotechnology Inc (Director · Since at least Jun 14, 2022); Sera Prognostics, Inc. (Chief Financial Officer · Mar 6, 2023 – Jun 7, 2023 · Past); Achieve Life Sciences, Inc. (Director · May 31, 2022 – May 31, 2022 · Past) | Director · Since at least Jun 10, 2022 |
| Krisztina M Zsebo Other companies: Eiger Biopharmaceuticals Inc (Chief Executive Officer, Director · Jan 29, 2014 – Apr 6, 2015 · Past) | Director · Dec 22, 2020 – Jun 10, 2022 · Past |
| Marvin Slosman Other companies: InspireMD Inc. (CEO and President, Director · Since at least Jan 23, 2024) | Director · Since at least Dec 2, 2025 |
| Subbarao V. Uppaluri Other companies: OPKO Health, Inc. (Director · Since at least Apr 14, 2010) | Director · Aug 11, 2016 – Aug 11, 2016 · Past |
| Andrew Scott Blank | Director · Since at least Sep 30, 2020 |
| Bill Facteau | President · Since at least Nov 4, 2026 |
| Bill Facteau | Director · Since at least Apr 23, 2025 |
| David McClung | CFO · Since at least Oct 24, 2016 |
| Debby Holmes-Higgin | VP of Clinical · Since at least Nov 5, 2026 |
| Derrick Romine | CFO of Cardo Medical, LLC · Aug 29, 2008 – Aug 29, 2008 · Past |
All 21 people
| Person | Seat |
|---|---|
| Edward Gillis | Sr. VP of Devices · Since at least Dec 8, 2025 |
| Eric Duckers | Chief Medical Officer · Oct 24, 2016 – Nov 2, 2020 · Past |
| Farhan Shahab | Vice President of Quality · Nov 24, 2025 – Nov 5, 2026 · Past |
| Fernando L Fernandez | Director · Jan 13, 2018 – Sep 30, 2020 · Past |
| Jim Allen | Since at least Nov 4, 2026 |
| Jim L Allen | Director · Since at least Oct 18, 2023 |
| Jonathan Brooks | Director · Oct 22, 2013 – May 10, 2016 · Past |
| Miranda Peto | Investor Relations · Since at least Oct 19, 2026 |
| Peter Altman | President and Chief Executive Officer · Since at least Oct 24, 2016 |
| Simon H. Stertzer | Board Member · Since at least Oct 24, 2016 |
| Thomas Quertermous | Director · Oct 24, 2016 – Jul 26, 2019 · Past |
Log in to ask 6ix AI your own questions about BioCardia, Inc.